Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more.
Eli Lilly is injecting some funding into Ionetix for the isotope manufacturer to expand its network of so-called cyclotrons for late-stage clinical and commercial services, according to a Wednesday release. Cyclotrons are machines that help produce isotopes. Lilly is contributing $10 million via a convertible loan, the Financial Times reports.
Lilly has finally revealed that it bought Nexus Pharma’s facility in Pleasant Prairie, WI, for $924.7 million, according to its second-quarter earnings report Thursday. Lilly announced it was buying the injectable facility in April but did not disclose any financial details.
The CDMO arm of Ajinomoto is laying off 71 workers in San Diego, CA, effective by the end of September, according to a WARN notice.
Fujifilm Holdings’ healthcare division, due to increased demand for its medical tools and CDMO services, saw its revenue jump by 10.8% and reaching JPY 229.2 billion ($1.6 billion) between April and June this year. Fujifilm cited high demand for its ADC manufacturing services.
Oxford Biomedica said there is “strong” demand for its viral vector manufacturing services. The cell and gene therapy CDMO reported it has signed £80 million ($101.9 million) in contracts as of July, which is expected to increase in the second half of 2024, according to its half-year earnings report. The company said customers are reserving manufacturing space for 2025 and it is looking to build on this demand. There are plans for its French sites to manufacture lentiviruses by the end of 2024.
Immuno-oncology company Agenus said in its earnings report Thursday that it has received partnership interest for its manufacturing facilities in North Carolina and its biologics site in Emeryville, CA.
Eurofins received a $22.4 million grant from the Canadian government to help the CDMO build a new facility to boost domestic production of antibodies and other protein-based therapies. The new facility will produce around 25 million commercial vials annually and will create 120 new jobs, according to a Wednesday release.
SK pharmteco has signed a memorandum of understanding with RNA-based gene therapy company Rznomics. This is a multi-year partnership to develop and commercialize gene therapies, according to a Monday release.
Eugia Pharma Specialities received an Official Action Indicated (OAI) response from the FDA following an inspection at its facility in Rajasthan, a northwestern state of India. The inspection was made between April 25 and May 3. Eugia said it is working with the FDA to resolve any issues at the site.
MIP Discovery has renamed itself to Tozaro, the first step in its transition to becoming a cell and gene therapy company. It will develop and manufacture viral vectors, the company said Tuesday.